Latest:
How Does IT Affect Quality of Care?
Oncology practices across the country are using computer technology to improve outcomes and quality of care for our patients.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Patrick I. Borgen, MD
Patrick I. Borgen, MD is the chair of the Department of Surgery and head of the Maimonides Breast Center at Maimonides Medical Center.
Latest:
Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer
Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.
Patrick Neven, MD, PhD
Latest:
Dr. Neven on the Relationship of Cell Cycle Genes and Outcomes in HR+/HER2– Breast Cancer
Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.
Patrick Ott, MD, PhD
Latest:
Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma
Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.
Paul B. Chapman, MD
Latest:
Dr. Chapman on Targeted Treatments for Non-Traditional Mutations in Melanoma
Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.
Paul D. Nathan, MBBS, PhD, FRCP
Latest:
Dr Nathan on the Design of the IMCgp100-202 Trial in Uveal Melanoma
Paul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.